Medicine Industry's Gateway to NICE

Pembrolizumab in combination with chemoradiotherapy is in clinical development for thetreatment of patients with high-risk, locally advanced cervical cancer. Cervical cancer ariseswhen abnormal cells lining the cervix begin to grow uncontrollably and create tumours. Cervicalcancer may not present symptoms, however the most common symptoms seen are unusualvaginal bleeding, pain during sex, vaginal discharge and pain […]

Momelotinib is currently in clinical development for the treatment of symptomatic myelofibrosiswith anaemia. Myelofibrosis is a rare blood cancer, where the bone marrow is too active so scartissue builds up inside the bone marrow and blood cells cannot develop properly. The reductionin blood cells can result in anaemia, amongst other symptoms such as tiredness, shortness […]

The port delivery system with ranibizumab (PDS) is in clinical development for the treatment ofdiabetic macular oedema (DMO). DMO is swelling of the macula caused by diabetes or byblockage of the veins behind the retina and it is the most common cause of sight loss in peoplewith diabetes. DMO occurs when blood vessels damaged by […]

Atezolizumab and bevacizumab in combination is in clinical development for treating adults with high riskof hepatocellular carcinoma (HCC) coming back (recurring), after complete surgical removal(resection/ablation) of the affected tissue. HCC is the most common type of primary liver cancer, whichaffects men more than women, and is more likely to develop the older a person gets.

Idecabtagene vicleucel is in clinical development for the treatment of adult patients with relapsedor refractory multiple myeloma (MM) who have received at least 2 but no greater than 4 priorMM regimens. MM is a rare, incurable blood cancer that forms in the plasma calls in the bonemarrow, inside some of the large bones of the […]

Baricitinib is in clinical development for children aged 1 to 17 years with juvenile idiopathicarthritis (JIA). JIA is defined as arthritis of unknown causes that manifests itself before the age of16 years and persists for at least 6 weeks, while excluding other known conditions. JIA occurswhen the body's immune system attacks its own cells and […]

Semaglutide is in clinical development for the treatment of overweight and obese adolescentsbetween the ages of 12 and 17. Obesity is a chronic disease and global public health challengeand the prevalence of childhood obesity rising in the UK. Obesity increases the risk of developinga range of health conditions in childhood and later life, including stroke, […]

Durvalumab with bevacizumab is intended to treat hepatocellular carcinoma (HCC), the mostcommon type of liver cancer, where there is a high risk of the cancer returning after curativetreatment. It is common that people with HCC are asymptomatic (do not show symptoms relatedto the cancer). There is increased risk of developing HCC if you have underlying […]

ABP 959 is in development for the treatment of paroxysmal nocturnal haemoglobinuria (PNH).PNH is a rare condition, which occurs due to a genetic mutation within stem cells in the bonemarrow. In PNH, red blood cells lack specific proteins on their surface which normally protectthem from being destroyed (a process called haemolysis) by the body's normal […]

Cenobamate is in clinical development as an adjunctive therapy for adults with primarygeneralized tonic-clonic (PGTC) seizures. A generalised tonic-clonic seizure is the type of epilepticseizure which is defined as a seizure that has a tonic phase (stiffening of the muscles) followed byclonic muscle contractions (rhythmical jerking).

A food allergy is when the body’s immune system reacts to proteins from specific foods, as if itwere a threat. Common foods that cause an allergic reaction are milk, eggs, peanuts, tree nuts,fish, and shellfish. Most food allergies affect younger children under the age of 3 years old,however peanut and tree nut allergies are longer-lasting […]

Gantenerumab is currently in clinical development for the treatment of early Alzheimer’s disease(AD). AD is a progressive neurological disease which is caused by loss of function and death ofneurones, the cells that carry signals or information messages to and from the brain and the restof the body. It is the most common type of dementia.

Odevixibat is currently in clinical development for the treatment of cholestatic liver disease in Alagille syndrome (ALGS) patients. ALGS is an inherited developmental disorder, caused by a mutation in the JAGGED1 gene or in the NOTCH2 gene. The mutation causes problems with early embryonic development leading to abnormalities in various parts of the body. ALGS […]

ASTX727 is in clinical development for patients with de novo or secondary acute myeloid leukaemia (AML), who are not candidates for standard induction chemotherapy. De novo AML is where there has been no past medical history of the condition or exposure to the drugs which commonly treat it, secondary AML is where patients have had […]

Natalizumab biosimilar is being developed as a biosimilar medicine to the approved monoclonal antibody natalizumab and is proposed to be used to treat adult patients relapsing remitting multiple sclerosis (RRMS). Multiple sclerosis is an autoimmune condition where the body’s immune system attacks the brain and nerves. RRMS is characterised by attacks of new or increasing […]

REGN5458 is in clinical development for the treatment of adults with multiple myeloma (MM) whose disease has returned following treatment. MM is a form of cancer that occurs in immune cells found in bone marrow. The disease occurs due to uncontrolled duplication of these immune cells, known as plasma cells. Symptoms of MM can include […]

Empagliflozin is in clinical development for the treatment of adult patients with chronic kidney disease (CKD). In CKD, the kidneys do not function as well as they should. This leads to the leakage of blood and protein into the urine. CKD can be developed due to age, but the main risk factors are diabetes, hypertension, […]

Fordadistrogene movaparvovec is a medicinal product in clinical development for the treatment of ambulatory boys with a confirmed genetic diagnosis of Duchenne muscular dystrophy (DMD). DMD is a severe and rare progressive neuromuscular disorder caused by a gene mutation (change). DMD is caused by an absence of functional dystrophin, a protein that helps keep muscle […]

Bimekizumab is in clinical development for the treatment of Hidradenitis Suppurativa (HS) in adults. HS is a painful, long-term skin condition that causes abscesses and scarring on the skin. The exact cause of hidradenitis suppurativa is unknown, but it occurs near hair follicles where there are sweat glands, usually around the groin, bottom, breasts and […]

Tislelizumab is being developed for the first-line treatment of unresectable hepatocellular carcinoma (HCC). HCC is the most common type of liver cancer and the leading cause of cancer related death worldwide. This type of cancer develops from the main liver cells, called hepatocytes. Liver cancer is more common in people who have long‐term damage to […]

Leniolisib is in clinical development for patients with Activated Phosphoinositide 3-kinase Delta Syndrome (APDS). APDS is an inherited disorder where the patient is unable to fight infections because the immune system (the body's natural defences) does not work properly. APDS is caused by defects in the genes that control the production of a protein called […]

Glucarpidase (Voraxaze), previously known as carboxypeptidase G2, is a carboxypeptidase G2 enzyme that hydrolyses the terminal glutamate residue from methotrexate.2 Glucarpidase hydrolyses methotrexate rapidly to the inactive metabolites DAMPA (4-[[2,4-diamino-6-(pteridinyl)methyl]-methylamino]-benzoic acid) and glutamate in patients with methotrexate-induced nephrotoxicity and delayed methotrexate excretion.3 It has been shown that the conversion of methotrexate to DAMPA relieves stress […]

Teduglutide is in clinical development for infants aged four to twelve months with short bowel syndrome (SBS) who are dependent on parenteral support (PS). SBS is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Consequently, individuals with SBS often […]

Amivantamab in combination with carboplatin-pemetrexed chemotherapy is in development forthe treatment of epidermal growth factor receptor (EGFR) exon 20 insertion mutations positivenon-small cell lung cancer (NSCLC). NSCLC is one of the most common types of cancer. EGFR isa protein found on certain types of cells that is involved in cell signalling pathways that controlcell division […]

Dexmedetomidine sublingual film is in clinical development for the treatment of agitationassociated with bipolar disorder. Bipolar disorder is mental health condition characterised byperiods of mania and severe depression. Agitation is a disruptive, and comorbid complication ofmany chronic mental illnesses, including bipolar disorders. Agitation is described as excessivemotor activity associated with a feeling of inner tension. […]

Schizophrenia is a severe long-term mental condition which can affect a person’s perception andinterpretation of the world around them. Symptoms include hallucinations (hearing and seeingthings), delusions (beliefs not based on reality) and agitation. It is not known what causesschizophrenia, but it is likely a combination of genetic and environmental factors. It affects bothmen and women […]

Ravulizumab is in clinical development for the treatment of neuromyelitis optica spectrumdisorder (NMOSD) NMOSD is a rare autoimmune disease where the immune system attacks thenerves in the eyes and central nervous system (CNS), which can result in weakness, paralysis, pain,blindness, and premature death. The condition often has frequent relapses which can result inprogressive disabilities for […]